Table 1 Clinico pathological features of 90 EOCs and 45 normal control patients
Parameters | CC-EOC | END-EOC | HGSC | Normal controls | ||
|---|---|---|---|---|---|---|
NE | OSE | TEC | ||||
Total number of cases | 14 | 26 | 50 | 15 | 20 | 10 |
Age (years) | ||||||
Median (range) | 57 (34–74) | 55 (39–72) | 60 (24–84) | 57 (50–71) | 53 (47–65) | 50 (42–55) |
Stage | ||||||
I-II | 11 | 15 | 7 | |||
III-IV | 3 | 11 | 43 | |||
Grade | ||||||
High | 14 | 14 | 50 | |||
Low | 0 | 12 | 0 | |||
Residual tumor (TR) | ||||||
TR = 0 cm | 11 | 19 | 15 | |||
TR > 0 cm | 3 | 7 | 35 | |||
Presence of ascites | ||||||
Yes | 3 | 15 | 35 | |||
No | 11 | 11 | 14 | |||
Na | 0 | 0 | 1 | |||
Neoplastic citology | ||||||
Negative | 8 | 11 | 8 | |||
Positive | 6 | 11 | 39 | |||
Not diagnostic | 0 | 4 | 3 | |||
Lymph nodes | ||||||
Negative | 11 | 17 | 21 | |||
Positive | 1 | 5 | 17 | |||
Na | 2 | 4 | 12 | |||
Platinum-based chemotherapy | ||||||
Yes | 14 | 23 | 50 | |||
No | 0 | 3 | 0 | |||
Response to first-line chemotherapy | ||||||
Complete | 12 | 25 | 37 | |||
Partial | 0 | 0 | 4 | |||
None | 2 | 1 | 8 | |||
Na | 0 | 0 | 1 | |||
Recurrence | ||||||
Yes | 5 | 12 | 30 | |||
No | 9 | 13 | 7 | |||
Na | 0 | 1 | 2 | |||
Progression | 0 | 0 | 11 | |||
Follow-up status | ||||||
Ned | 8 | 13 | 10 | |||
Awd | 0 | 3 | 3 | |||
Dod | 6 | 8 | 35 | |||
Did | 0 | 1 | 2 | |||
Lost | 0 | 1 | 0 | |||
Platinum status | ||||||
Sensitive | 10 | 19 | 27 | |||
Partially sensitive | 0 | 2 | 7 | |||
Resistant | 4 | 2 | 16 | |||
Na | 0 | 3 | 0 | |||